Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
about
Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune DiseasesParainflammation, chronic inflammation, and age-related macular degenerationCurrent concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum.Dysregulation in retinal para-inflammation and age-related retinal degeneration in CCL2 or CCR2 deficient mice.Road to fulfilment: taming the immune response to restore vision.Autoimmune and autoinflammatory mechanisms in uveitis.High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutationInhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responsesPrevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.Emerging role of antioxidants in the protection of uveitis complications.Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid.Chlamydial induction of hydrosalpinx in 11 strains of mice reveals multiple host mechanisms for preventing upper genital tract pathologyInterplay between innate and adaptive immunity in the development of non-infectious uveitisAssociation of Complement C5 Gene Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Han Population.Copy number variations and gene polymorphisms of complement components in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.C5a and toll-like receptor 4 crosstalk in retinal pigment epithelial cells.Targeting the complement system for the management of retinal inflammatory and degenerative diseases.The future of uveitis treatmentDynamic control of the complement system by modulated expression of regulatory proteins.Proteomic Profiling Analysis Reveals a Link between Experimental Autoimmune Uveitis and Complement Activation in Rats.From compliment to insult: genetics of the complement system in physiology and disease in the human retina.The complement anaphylatoxin receptors are not required for the development of experimental autoimmune uveitis.Melatonin decreases brain apoptosis, oxidative stress, and CD200 expression and increased survival rate in mice infected by Venezuelan equine encephalitis virus.Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU).Complement Component C4 Regulates the Development of Experimental Autoimmune Uveitis through a T Cell-Intrinsic Mechanism.Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis.Increased Complement 3a Receptor is Associated with Behcet's disease and Vogt-Koyanagi-Harada disease.C5aR activation in the absence of C5a: A new disease mechanism of autoimmune hemolytic anemia in mice.The role of microglia in the progression of glaucomatous neurodegeneration- a review.The Complement System Is Critical in Maintaining Retinal Integrity during Aging.Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.Expression of Complement Components and Regulators by Different Subtypes of Bone Marrow-Derived Macrophages
P2860
Q26766486-13A2EA89-7A3B-41C4-8F11-C23A477282C3Q26796268-ECC318FF-E513-4A14-A427-51D885D4B074Q27693189-F994C5B7-E1F4-4A85-8683-C672C47D794DQ33899705-5F4EB5CC-F0F1-4291-BDEA-9A6EB95E6BDDQ33995590-02B57FB9-3A85-4321-ADD9-7E87CF7899ACQ34259510-793DB47E-5814-4586-BC34-82DF9BA67A12Q34294964-831CA2C3-A66B-498A-86B8-4A6912929C44Q34482369-BCBB636C-050F-4481-9C03-3ED0D4933520Q34624453-6BDF1213-4F64-4AAF-ACBE-4D10D02C21CFQ34625994-47D64094-A62B-4182-BF84-C9509839B958Q34887046-EAD9766A-67D8-499F-955A-9336F23AE84DQ35068037-4B8A71ED-C049-4A24-8429-029E0E81DC0BQ35149009-34BBC483-C914-4466-82F7-8A04DF63D760Q35784059-2557A0C3-D01E-43BE-8715-6E4331FB8ED7Q35943170-623EB40F-F8F7-4CAB-8010-0CDEEEC32746Q35947745-FD27CE36-3428-4228-B9EA-C616A6E3D445Q36107219-B7D4C408-2117-4B8A-9F04-A357CC8E8914Q37262287-7D11B0AF-1402-4016-AE43-F2F6FF3B71B2Q37554382-56BA312A-EA49-4228-88D7-A9EBD8B1944AQ37797869-34068FFC-5371-4893-B0D6-18D57C78E280Q38436935-3A8E18FC-FEB2-45C9-9AE2-FA40D53AD67AQ39290950-92DFC8DD-F172-4BD7-9CF2-C0FA55885E8EQ40234582-7BC07366-E136-45AF-B82D-80C6976D52C8Q40583344-3DE6178E-4D71-44C4-8AAC-44AA30371F36Q41436924-092C7B1A-3BB5-42D0-B34A-3D078FA71C5DQ41684149-F451F1FC-8447-4AD2-B2E6-5868DB7C9B75Q42921553-CF034E9E-3F93-4268-919D-1CB0193D37D2Q47107353-CE2F7082-2471-4B1E-A579-DFCBE22E4B9CQ48349917-8750441A-6561-4682-A5E5-2917B2556C65Q49192854-1D24E8CA-0A1D-4134-8CB9-A40546BC0D15Q51766201-BDFC41FD-CA4B-4DEB-AD98-2AE3F2876FA4Q52313908-34D9F182-B4C0-4BD2-86E3-5907CE78A5BEQ57278869-9FD9520A-4E9D-4CD3-8669-0D76EC8C82DB
P2860
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@en
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@nl
type
label
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@en
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@nl
prefLabel
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@en
Systemic and local anti-C5 the ...... ntal autoimmune uveoretinitis.
@nl
P2093
P2860
P1476
Systemic and local anti-C5 the ...... ental autoimmune uveoretinitis
@en
P2093
D A Copland
L B Nicholson
S Baalasubramanian
T R Hughes
P2860
P304
P356
10.1111/J.1365-2249.2009.04070.X
P577
2009-12-04T00:00:00Z